Your browser doesn't support javascript.
loading
Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
Röhrich, Manuel; Koelsche, Christian; Schrimpf, Daniel; Capper, David; Sahm, Felix; Kratz, Annekathrin; Reuss, Jana; Hovestadt, Volker; Jones, David T W; Bewerunge-Hudler, Melanie; Becker, Albert; Weis, Joachim; Mawrin, Christian; Mittelbronn, Michel; Perry, Arie; Mautner, Victor-Felix; Mechtersheimer, Gunhild; Hartmann, Christian; Okuducu, Ali Fuat; Arp, Mirko; Seiz-Rosenhagen, Marcel; Hänggi, Daniel; Heim, Stefanie; Paulus, Werner; Schittenhelm, Jens; Ahmadi, Rezvan; Herold-Mende, Christel; Unterberg, Andreas; Pfister, Stefan M; von Deimling, Andreas; Reuss, David E.
Affiliation
  • Röhrich M; Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Koelsche C; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schrimpf D; Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Capper D; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sahm F; Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Kratz A; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Reuss J; Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Hovestadt V; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jones DT; Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Bewerunge-Hudler M; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Becker A; Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Weis J; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mawrin C; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mittelbronn M; Division of Molecular Genetics, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Perry A; Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mautner VF; Genomics and Proteomics Core Facility, Microarray Unit, German Cancer Research Center (DKFZ), INF 580, Heidelberg, Germany.
  • Mechtersheimer G; Institute of Neuropathology, University Medical Center, Bonn, Germany.
  • Hartmann C; Institute of Neuropathology, Rheinisch-Westfälische Technische Hochschule, Aachen University Hospital, Aachen, Germany.
  • Okuducu AF; Department of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany.
  • Arp M; Institute of Neurology (Edinger Institute), Goethe University, Frankfurt, Germany.
  • Seiz-Rosenhagen M; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hänggi D; Division of Neuropathology, University of California, San Francisco, USA.
  • Heim S; Department of Neurology, University Hospital Hamburg Eppendorf, 20246, Hamburg, Germany.
  • Paulus W; Department of General Pathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
  • Schittenhelm J; Department of Neuropathology, Hannover Medical School, Hannover, Germany.
  • Ahmadi R; Department of Pathology, Municipal Hospital Nürnberg, Nuremberg, Germany.
  • Herold-Mende C; Department of Neurosurgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Unterberg A; Department of Neurosurgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Pfister SM; Department of Neurosurgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • von Deimling A; Institute of Neuropathology, University Hospital, Muenster, Germany.
  • Reuss DE; Institute of Neuropathology, University Hospital, Muenster, Germany.
Acta Neuropathol ; 131(6): 877-87, 2016 06.
Article in En | MEDLINE | ID: mdl-26857854
The vast majority of peripheral nerve sheath tumors derive from the Schwann cell lineage and comprise diverse histological entities ranging from benign schwannomas and neurofibromas to high-grade malignant peripheral nerve sheath tumors (MPNST), each with several variants. There is increasing evidence for methylation profiling being able to delineate biologically relevant tumor groups even within the same cellular lineage. Therefore, we used DNA methylation arrays for methylome- and chromosomal profile-based characterization of 171 peripheral nerve sheath tumors. We analyzed 28 conventional high-grade MPNST, three malignant Triton tumors, six low-grade MPNST, four epithelioid MPNST, 33 neurofibromas (15 dermal, 8 intraneural, 10 plexiform), six atypical neurofibromas, 43 schwannomas (including 5 NF2 and 5 schwannomatosis associated cases), 11 cellular schwannomas, 10 melanotic schwannomas, 7 neurofibroma/schwannoma hybrid tumors, 10 nerve sheath myxomas and 10 ganglioneuromas. Schwannomas formed different epigenomic subgroups including a vestibular schwannoma subgroup. Cellular schwannomas were not distinct from conventional schwannomas. Nerve sheath myxomas and neurofibroma/schwannoma hybrid tumors were most similar to schwannomas. Dermal, intraneural and plexiform neurofibromas as well as ganglioneuromas all showed distinct methylation profiles. Atypical neurofibromas and low-grade MPNST were indistinguishable with a common methylation profile and frequent losses of CDKN2A. Epigenomic analysis finds two groups of conventional high-grade MPNST sharing a frequent loss of neurofibromin. The larger of the two groups shows an additional loss of trimethylation of histone H3 at lysine 27 (H3K27me3). The smaller one retains H3K27me3 and is found in spinal locations. Sporadic MPNST with retained neurofibromin expression did not form an epigenetic group and most cases could be reclassified as cellular schwannomas or soft tissue sarcomas. Widespread immunohistochemical loss of H3K27me3 was exclusively seen in MPNST of the main methylation cluster, which defines it as an additional useful marker for the differentiation of cellular schwannoma and MPNST.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Neurofibromatoses / Nerve Sheath Neoplasms / Neurilemmoma Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Acta Neuropathol Year: 2016 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Neurofibromatoses / Nerve Sheath Neoplasms / Neurilemmoma Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Acta Neuropathol Year: 2016 Type: Article Affiliation country: Germany